Esophageal Squamous Cell Carcinoma Clinical Trial
Official title:
The THINKER Study: A Pilot for a Case-Control of Esophageal Squamous Cell Carcinoma in Western Kenya
Background:
- Esophageal cancer is the sixth leading cause of cancer deaths worldwide. Two primary
cell types, squamous cell carcinoma and adenocarcinoma, account for most cases. Of the
two, esophageal squamous cell carcinoma (ESCC) accounts for more than 80 percent of all
deaths from esophageal cancer. Many cases occur in certain areas with defined geographic
boundaries, including parts of Kenya.
- Studies of ESCC in developed countries (such as the United States) suggest that heavy
tobacco and alcohol use, poor diet, and low socioeconomic status are the primary risk
factors. Males and African Americans are also at higher risk. However, these risk
factors do not fully explain the prevalence of cases in several of the identified
geographic areas.
- ESCC is the most common cancer seen at Tenwek Hospital in western Kenya, and a notable
number of patients are 30 years of age or younger.
Objectives:
- To test the feasibility of a new protocol by recruiting visitors to Tenwek Hospital and
volunteers from the general population for study purposes.
- To use the new protocol to obtain blood and urine samples from ESCC cases in Tenwek
Hospital and from nonpatient volunteers.
Eligibility:
- Hospital patients and volunteers who live within 50 kilometers of Tenwek Hospital in
western Kenya.
Design:
- All participants will complete a questionnaire and provide blood and urine samples for
testing.
- The questionnaire will include questions about individual and family medical
history, living conditions, lifestyle, habits, and diet.
- Blood and urine samples will be collected from all participants after the
questionnaire.
- Biological samples will be shipped to the United States for further testing.
- Treatment will not be offered as part of this study.
This pilot study will assess the feasibility of completing the first formal case-control
study to examine etiologic factors for esophageal squamous cell carcinoma (ESCC) in Kenya and
will be conducted in Western Kenya, a high-risk area for ESCC.
Esophageal cancer causes over 380,000 deaths per year and ranks as the sixth leading cause of
cancer death worldwide. Two primary cell types, squamous cell carcinoma and adenocarcinoma,
account for most cases. Although the rates of esophageal adenocarcinoma have risen rapidly in
the United States and elsewhere, ESCC still accounts for 80% of all esophageal cancer cases
in the world. Many of these cases occur in high-risk areas with sharp geographic boundaries
within China, Iran, a small region of South America, South Africa, and Kenya. Studies of ESSC
in economically developed countries, such as the US, point to smoking tobacco, heavy alcohol
drinking, poor diets deficient in fresh fruits and vegetables, and low socioeconomic status
as the main etiologic factors. Other independent risk factors may include being male and
being African-American. Smoking tobacco and heavy alcohol consumption do not explain the
incidence rates in the high-risk regions because these habits are less common and less
intensely practiced in these high-risk areas compared to the low risk area. Also, in highrisk
areas the incidence rates are similar in men and women despite differences in the rates of
tobacco smoking and alcohol drinking. Therefore, it is important to consider a wide range of
etiologic factors to explain the high rates of cancer in these populations.
Tenwek Hospital is a 300 bed mission hospital located in Bomet District, Rift Valley
Province, approximately 200 miles from Nairobi in the west of Kenya. Tenwek serves as a
primary health care facility for approximately 400,000 people, and it has become a referral
center for a broader population. ESCC is the most common malignancy seen at Tenwek Hospital
and the patients show a very unusual age distribution with 10% of cases less than or equal to
30 years of age.
We will conduct a pilot for a case-control study of ESCC at Tenwek Hospital, recruiting
people that live within 50 km of the hospital. Initial pilot testing showed that neither
hospital-visitor controls nor general-population controls were practical control sources. We
now plan to test the feasibility of collecting 50 hospital-based non-cancer patient controls.
We will then enroll 50 cases and 50 additional hospital-based non-cancer patient controls to
test all aspects of our protocol. We will ship the biological samples collected from these
individuals to the US and test their suitability for our intended assays. All subjects will
be interviewed using a structured questionnaire and will be asked to provide biological
samples including blood and urine. Environmental risk factors (including lifestyle, habits,
and diet) will be assessed through questionnaires.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06056336 -
Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
|
Phase 2 | |
| Suspended |
NCT04084158 -
A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.
|
Phase 2 | |
| Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT05561699 -
Sequential Preoperative Penpulimab Combined With Chemoradiotherapy(CRT) for Locally Advanced Esophageal Squamous Cell Cancer
|
N/A | |
| Active, not recruiting |
NCT04543617 -
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
|
Phase 3 | |
| Recruiting |
NCT06190782 -
Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
|
Phase 3 | |
| Completed |
NCT05557955 -
Identification of Breath Biomarkers in Esophageal Cancer
|
||
| Recruiting |
NCT04045496 -
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
| Not yet recruiting |
NCT03766178 -
Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT02913066 -
S-1 IMRT Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
| Completed |
NCT02399306 -
Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma
|
Phase 3 | |
| Completed |
NCT01605305 -
Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05552651 -
Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05520619 -
Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)
|
Phase 2 | |
| Terminated |
NCT03251417 -
Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05990231 -
Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy
|
Phase 2 | |
| Recruiting |
NCT04644250 -
Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
| Completed |
NCT02916511 -
Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
| Terminated |
NCT04032704 -
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
|
Phase 2 |